The Green Organic Dutchman Holdings Limited

Unaudited Interim Condensed Consolidated Financial Statements

For the three and six months ended June 30, 2019 and 2018



The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited)

(expressed in thousands of Canadian dollars, except common shares outstanding)

Refundable sales taxes receivable Trade receivables Biological assets Inventories Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Property, plant and equipment Intangible assets Goodwill Investments in associates Loans receivable Other assets 9, Total assets Income tax payable and accrued liabilities Income tax payable and accrued liabilities Income tax payable Short-term loans Current liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital	\$ 15 16 4 5 \$ 13 6 7 7 8 9 5 5 [a] \$ \$ 5 5 5 5 5 5 5 5 5 5 5 5 5	68,715 54,000 13,813 2,770 312 4,222 6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416 32,479	50,000 13,332 1,199 395 3,925 3,521 800 864 \$	\$ \$	213,549 50,000 13,332 1,199 395 3,925 3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151 29,878
Cash and cash equivalents Restricted cash Refundable sales taxes receivable Trade receivables Biological assets Inventories Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Non-current assets Goodwill Investments in associates Loans receivable Other assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current liabilities Lease liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	15 16 4 5 \$ \$ \$ \$ \$ \$ \$ \$	54,000 13,813 2,770 312 4,222 6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	50,000 13,332 1,199 395 3,925 3,521 800 864 \$ 287,585 108,808 13,535 10,702 10,944 1,001 14,661 \$ 447,236 \$ 28,258 781 688 263	\$ \$	50,000 13,332 1,199 395 3,925 3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Restricted cash Refundable sales taxes receivable Trade receivables Biological assets Inventories Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Inventories Property, plant and equipment Intangible assets Goodwill Investments in associates Loans receivable Other assets UIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans I: Current liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	15 16 4 5 \$ \$ \$ \$ \$ \$ \$ \$	54,000 13,813 2,770 312 4,222 6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	50,000 13,332 1,199 395 3,925 3,521 800 864 \$ 287,585 108,808 13,535 10,702 10,944 1,001 14,661 \$ 447,236 \$ 28,258 781 688 263	\$ \$	50,000 13,332 1,199 395 3,925 3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Refundable sales taxes receivable Trade receivables Biological assets Inventories Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Property, plant and equipment Intangible assets Goodwill Investments in associates Loans receivable Other assets Vother assets Value Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability	16 4 5 5 \$ 4], 6 7 7 7 8 9 5[a] \$ \$ 5[a] \$ \$ 5[a] \$ 5[a]	13,813 2,770 312 4,222 6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	13,332 1,199 395 3,925 3,521 800 864 \$ 287,585 108,808 13,535 10,702 10,944 1,001 14,661 \$ 447,236 \$ 28,258 781 688 263	\$ _	13,332 1,199 395 3,925 3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Trade receivables Biological assets Inventories Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Non-current assets Non-current assets Goodwill Investments in associates Loans receivable Other assets ILABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans 1:: Current portion of lease liabilities Non-current liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	4 5 5 8 7 7 8 9 .5[a] \$ \$ [[e] 11	2,770 312 4,222 6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	1,199 395 3,925 3,521 800 864 \$ 287,585 108,808 13,535 10,702 10,944 1,001 14,661 \$ 447,236 \$ 28,258 781 688 263	\$ _	1,199 395 3,925 3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Biological assets Inventories Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Non-current assets Reproperty, plant and equipment Investments in associates Loans receivable Other assets ILABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans I: Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Share capital Contributed surplus Deficit	4 5 5 8 7 7 8 9 .5[a] \$ \$ [[e] 11	312 4,222 6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	395 3,925 3,521 800 864 \$ 287,585 108,808 13,535 10,702 10,944 1,001 14,661 \$ 447,236 \$ 28,258 781 688 263	\$ _	395 3,925 3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Inventories Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Non-current assets Non-current assets Goodwill Investments in associates Loans receivable Other assets ULABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans 1: Current portion of lease liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Share capital Contributed surplus Deficit	5 5 8 9 5[a] \$ \$ [[e] 11	4,222 6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	3,925 3,521 800 864 \$	\$ _	3,925 3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Prepaid expenses and deposits Due from related parties Other current assets Non-current assets Property, plant and equipment Intangible assets Goodwill Investments in associates Loans receivable Other assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Income tax payable and accrued liabilities Income tax payable Short-term loans I: Current portion of lease liabilities Non-current liabilities Lease liabilities Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	\$ 4], 6 7 7 8 9 5[a] \$ \$ \$ [[e] 1]	6,201 898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	3,521 800 864 \$	\$ _	3,521 800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Due from related parties Other current assets Property, plant and equipment Intangible assets Goodwill Investments in associates Loans receivable Other assets 1 17 tal assets 1 1 Total assets 1 1 Total assets 1 1 Total assets 1 1 Total assets 1 1 Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Lease liabilities Contingent consideration Deferred tax liability 1 1 1 1 1 1 1 1	a], 6 7 7 8 9 5[a] \$ \$ ([e] 1	898 448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	800 864 \$	\$ _	800 864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Other current assets Non-current assets Property, plant and equipment 3[Intangible assets Goodwill Investments in associates Loans receivable Other assets 9, Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans 11: Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability	a], 6 7 7 8 9 5[a] \$ \$ ([e] 1	448 151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	864 287,585 108,808 13,535 10,702 10,944 1,001 14,661 \$ 447,236 \$ 28,258 781 688 263	\$ _	864 287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Non-current assets Property, plant and equipment 3[Intangible assets 3[Goodwill 1 Investments in associates 2 Loans receivable 0 Other assets 9, Total assets 9, LIABILITIES AND SHAREHOLDERS' EQUITY 2 Current liabilities 4 Accounts payable and accrued liabilities 1 Income tax payable 11 Short-term loans 12 Current portion of lease liabilities 12 Non-current liabilities 12 Current portion of lease liabilities 12 Total liabilities 13 Contingent consideration 14 Deferred tax liability 14 Total liabilities 14 Share capital 14 Contributed surplus 15 Deficit 14	a], 6 7 7 8 9 5[a] \$ \$ ([e] 1	151,379 211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	\$ 287,585 108,808 13,535 10,702 10,944 1,001 14,661 \$ 447,236 \$ 28,258 781 688 263	\$ _	287,585 107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Property, plant and equipment 3[Intangible assets Goodwill Investments in associates Loans receivable Other assets 9, Total assets 9, Total assets 9, LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities 1 Income tax payable 5 Short-term loans 1 Current liabilities 1 Current portion of lease liabilities 1 Current liabilities 1 Current portion of lease liabilities 1 Total liabilities 1 Share consideration 1 Deferred tax liability 1 Total liabilities 1 Share capital 1 Contributed surplus 1 Deficit 1	a], 6 7 7 8 9 5[a] \$ \$ ([e] 1	211,240 14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	108,808 13,535 10,702 10,944 1,001 14,661 \$	\$ _	107,529 13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Property, plant and equipment 3[Intangible assets Goodwill Investments in associates Loans receivable Other assets 9, Total assets 9, Total assets 9, LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities 1 Income tax payable 5 Short-term loans 1 Current liabilities 1 Current portion of lease liabilities 1 Current liabilities 1 Current portion of lease liabilities 1 Total liabilities 1 Share consideration 1 Deferred tax liability 1 Total liabilities 1 Share capital 1 Contributed surplus 1 Deficit 1	7 7 8 9 5[a] \$ \$ ([e] 11	14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	13,535 10,702 10,944 1,001 14,661 \$		13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Intangible assets Goodwill Investments in associates Loans receivable Other assets 9, Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans 1: Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	7 7 8 9 5[a] \$ \$ ([e] 11	14,540 10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	13,535 10,702 10,944 1,001 14,661 \$		13,535 10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Goodwill Investments in associates Loans receivable Other assets 9, Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans 1: Current portion of lease liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	7 8 9 5[a] \$ \$ (§] 1	10,287 9,897 2,452 36,462 436,257 30,562 969 532 416	10,702 10,944 1,001 14,661 \$		10,702 10,944 1,001 14,661 445,957 28,258 781 688 151
Investments in associates Loans receivable Other assets 9, Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans 1: Current portion of lease liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	8 9 5[a] \$ \$ [6] 1	9,897 2,452 36,462 436,257 30,562 969 532 416	10,944 1,001 14,661 \$		10,944 1,001 14,661 445,957 28,258 781 688 151
Loans receivable Other assets 9, Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans 1: Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	9 5[a] \$ \$ [6] 1	2,452 36,462 436,257 30,562 969 532 416	1,001 14,661 \$ <u>447,236</u> \$ <u>28,258</u> 781 688 263		1,001 14,661 445,957 28,258 781 688 151
Other assets 9, Total assets 1 LIABILITIES AND SHAREHOLDERS' EQUITY 1 Current liabilities 1 Accounts payable and accrued liabilities 1 Income tax payable 1 Short-term loans 1 Current portion of lease liabilities 1 Non-current liabilities 1 Lease liabilities 1 Contingent consideration 1 Deferred tax liability 1 Total liabilities 1 Shareholders' equity 1 Share capital 1 Contributed surplus 1 Deficit 1	5[a] \$ \$ 5[e] 11	36,462 <u>436,257</u> 30,562 969 532 416	14,661 \$ <u>447,236</u> \$ <u>28,258</u> 781 688 263		14,661 445,957 28,258 781 688 151
Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	\$ \$ 5[e] 11	436,257 30,562 969 532 416	\$ <u>447,236</u> \$ <u>28,258</u> 781 688 263		445,957 28,258 781 688 151
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	\$ 5[e] 11	30,562 969 532 416	\$ 28,258 781 688 263		28,258 781 688 151
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	\$ 5[e] 11	30,562 969 532 416	\$ 28,258 781 688 263		28,258 781 688 151
Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	5[e] 1	969 532 416	781 688 263	\$	781 688 151
Current liabilities Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	5[e] 1	969 532 416	781 688 263	\$	781 688 151
Accounts payable and accrued liabilities Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	5[e] 1	969 532 416	781 688 263	\$	781 688 151
Income tax payable Short-term loans Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	5[e] 1	969 532 416	781 688 263	\$	781 688 151
Short-term loans 1: Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	11	532 416	688 263		688 151
Current portion of lease liabilities Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	11	416	263		151
Non-current liabilities Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit					
Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit		32,479	29,990		29,878
Lease liabilities Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit			29,990		
Contingent consideration Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit					
Deferred tax liability Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	1	1,456	1,468		261
Total liabilities Shareholders' equity Share capital Contributed surplus Deficit	10	488	688		688
Shareholders' equity Share capital Contributed surplus Deficit	13	1,209	1,435		1,435
Shareholders' equity Share capital Contributed surplus Deficit		3,153	3,591		2,384
Share capital Contributed surplus Deficit	\$	35,632	\$ 33,581	\$	32,262
Share capital Contributed surplus Deficit					
Contributed surplus Deficit					
Deficit		406,004	392,068		392,068
	12	85,678	79,937		79,937
Reserve for foreign translations		(89,310)	(58,863)	(58,823)
		(1,540)	513		513
Total Shareholders' Equity attributed to The Green Organic			A	<u> </u>	
Dutchman Holdings Ltd.	\$	400,832	\$ 413,655	\$	413,695
Non-controlling interests		(207)	_		—
Total Shareholders' Equity		400,625	413,655		413,695
Total Liabilities and Shareholders' Equity	\$	436,257	\$ 447,236	\$ _	445,957
Total number of common shares outstanding		375 446 000	269,976,624	-	269,976,624
Business combination		275,446,088			
	10	275,446,088			
Events after the reporting period	10 15	2/3,446,088			

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (Unaudited)

(expressed in thousands of Canadian Dollars, except per share amounts)

					ths ended	For the six months ended		
	Notes		e 30,)19		June 30, 2018		June 30, 2019	June 30, 2018
Revenue	:	\$	2,896	\$	_	\$	5,301 \$	_
Cost of sales related to inventory production			944		_		1,927	_
Cost of sales related to business combination fair value adjustments to								
inventories				_			270	
Gross profit before change in fair value of biological assets			1,952		_		3,104	_
Realized fair value adjustment on sale of inventory			(5))			(5)	
Unrealized gain on changes in fair value of biological assets	4		10	<u>^</u>			225	
Gross profit	1	\$	1,957	\$	_	\$	3,324 \$	-
Operating expenses								
Sales and marketing expenses	5	\$	3,930	\$	662	\$	6,926 \$	1,490
Research and development expenses			586		1,061		1,022	1,576
General and administrative expenses			8,687		5,417		17,366	9,222
Share based compensation	12		4,433		1,751		7,852	3,925
Depreciation and amortization	6, 7		738		181		1,299	320
Total operating expenses	1	\$	18,374	\$	9,072	\$	34,465 \$	16,533
Loss from operations			(16,417))	(9,072)		(31,141)	(16,533)
Strategic business initiatives			(606)				(606)	
Share of loss on investments in associates	8		(230)		_		(452)	_
Revaluation of contingent consideration	10		175		_		200	_
Foreign exchange loss	10		(315)		_		(475)	_
Finance income			869		572		2,055	767
Finance costs			(143)		(48)		(232)	(48)
		-	(145)		(10)	_	(252)	(40)
Loss before income taxes			(16,667))	(8,548)		(30,651)	(15,814)
Current income tax expense			(93))			(214)	
Deferred income tax recovery	13		157				171	
Net loss	1	\$	(16,603)	\$	(8,548)	\$	(30,694) \$	(15,814)
Other comprehensive loss								
Foreign currency translation loss			156		_		1,458	_
Foreign currency translation loss on equity method investment	8		547		_		595	
Comprehensive loss		\$	<u>(17,306</u>)	\$	(8,548)	\$	(32,747) \$	(15,814)
.								
Net loss attributable to:			(1 (4 40)		(0 540)		(20.447)	(15.01.4)
The Green Organic Dutchman Holdings Ltd.			(16,440)		(8,548)		(30,447)	(15,814)
Non-controlling interests			(163))			(247)	_
Comprehensive loss attributable to:								
The Green Organic Dutchman Holdings Ltd.			(17,143)		(8,548)		(32,500)	(15,814)
Non-controlling interests			(163))	_		(247)	_
Basic and diluted net loss per share		\$	(0.06)	\$	(0.04)	\$	(0.11) \$	(0.09)
1	,		<u> </u>				<u> </u>	
Weighted average number of outstanding common shares		275,	165,384		04,647,837	=	273,234,673	180,483,659

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)

(expressed in thousands of Canadian Dollars, except number of shares)

	Number of shares	Share capital	Contributed surplus	Reserve for foreign <u>translations</u>	Accumulated deficit	Non- Controlling Interests	Total
DI (DI 21 2010	#	\$	\$	\$	\$	\$	\$
Balance at December 31, 2018	269,976,624	392,068	79,937	513	(58,823)		413,695
Effect of adoption of IFRS 16					(40)		(40)
Balance at January 1, 2019	269,976,624	392,068	79,937	513	(58,863)		413,655
Share based compensation	—	38	3,381	—	—	_	3,419
Exercise of stock options	134,800	176	(73)	_	_	—	103
Exercise of warrants	4,264,354	10,937	(1,749)	_	_	—	9,188
Cancellation of shares	(5,880)	_	_	_	_	_	_
Contribution from non-controlling interest	—	—	_	_	_	40	40
Comprehensive loss for period	—	—	_	(1,350)	(14,007)	(84)	(15,441)
Balance at March 31, 2019	274,369,898	403,219	81,496	(837)	(72,870)	(44)	410,964
Share based compensation	_	26	4,407	_	_	_	4,433
Exercise of stock options	235,133	351	(135)	_	_	_	216
Exercise of warrants	841,057	2,408	(390)	—	_	—	2,018
Issuance of convertible units	—	_	300	_	_	_	300
Comprehensive loss for period		—	_	(703)	(16,440)	(163)	(17,306)
Balance at June 30, 2019	275,446,088	406,004	85,678	(1,540)	(89,310)	(207)	400,625

	Number of shares	Share capital	Contributed surplus	Accumulated deficit	Total
	#	\$	\$	\$	\$
Balance as at January 1, 2018	142,594,801	72,572	18,296	(13,620)	77,248
Private placement of units	14,134,566	18,247	4,359	_	22,606
Finders' compensation - Units	692,290	935	208	_	1,143
Share based compensation	1,662,000	2,302	(1,272)	_	1,030
Exercise of stock options	18,000	16	(7)	_	9
Share issue costs	_	(760)	_	_	(760)
Comprehensive loss for period	_	—	_	(7,266)	(7,266)
Balance at March 31, 2018	159,101,657	93,312	21,584	(20,886)	94,010
Initial public offering	31,510,000	106,504	8,508	_	115,012
Initial public offering - over-allotment	4,726,500	15,975	1,277	_	17,252
Conversion of subscription agreements	33,333,334	28,227	26,773	_	55,000
Exercise of stock options	637,400	682	(291)	_	391
Exercise of warrants	4,746,677	13,810	(340)	_	13,470
Issuance of special warrants	_	—	25,024	_	25,024
Issuance of underwriter special warrants	—	—	610	—	610
Stock based compensation	_	30	1,722	_	1,752
Share issue costs	_	(6,180)	(2,995)	_	(9,175)
Cancellation of shares	(250,000)	_	_	_	-
Net loss and comprehensive loss	_	_	_	(8,548)	(8,548)
Balance at June 30, 2018	233,805,568	252,360	81,872	(29,434)	304,798

An unlimited number of common shares are authorized for issue.

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(expressed in thousands of Canadian dollars)

	N-4	For the three		For the six m	
	Notes	June 30, 2019	June 30, 2018	June 30, 2019	June 30, 2018
OPERATING ACTIVITIES			(Recast - Note 3)		(Recast - Note 3)
Net loss	s	6 (16,603) \$	(8,548)	\$ (30,694) \$	6 (15,814)
Items not affecting cash:	1) (10,003) ¢	(0,540) 3	6 (30,094) 4	6 (13,014
Share based compensation - finders' units	12		<u> </u>	<u> </u>	1,142
Share based compensation - inders and options	12	4,404	1.752	7,800	2,782
Share based compensation - restricted share units	12	29	1,752	52	2,762
Convertible share units issued	12	300	_	300	
Depreciation of property, plant and equipment	6	422	102	684	167
Amortization of intangible assets	7	316	79	615	153
Unrealized gain on change in fair value of biological assets	4	(10)	13	(225)	155
Share of loss from investments in associates	8	230	_	452	
Revaluation of contingent consideration	10	(175)	_	(200)	
Loss on disposals of property, plant and equipment	6	(175)	_	(200)	_
Current income tax expense	0	93	_	214	
Deferred income tax recovery	13		_		_
	15	(157)	_	(171)	_
Income taxes paid Changes in non-cash operating working capital items	14	(26)	(8,578)	(26)	(0 226
		(13,378)	· · · · · · · · · · · · · · · · · · ·	(24,513)	(8,226
Net cash used in operating activities	ş	5 (24,526) \$	(15,193) 9	\$ (45,676) \$	6 (19,796
INVESTING ACTIVITIES					
Additions to property, plant and equipment	6	(77,274)	(13,102)	(103,270)	(16,525
Net cash outflow on investment in associates	8	_	_	_	(2,171
Transfer to restricted cash	15[a]	(4,000)	—	(4,000)	_
Net cash outflow on other investment	9	(1,434)	—	(1,434)	_
Additions to intangible assets	7	(957)	(200)	(1,870)	(200
Net cash used in investing activities	\$	6 (83,665) \$	(13,302) \$	\$ (110,574) \$	6 (18,896
FINANCING ACTIVITIES					
Proceeds from issuance of shares and warrants, net of share issue costs	5	_	204,693	_	226,539
Proceeds from the exercise of stock options		216	390	319	399
Proceeds from the exercise of warrants		2.018	12,501	11,206	12,501
Interest received		2,014	515	2,388	569
Interest paid on lease liabilities		(61)	_	(61)	
Principal payments of lease liabilities		(164)	_	(164)	_
Loan receivable	9	(1,451)	_	(1,451)	(1,001
Repayments of short-term loans		15	_	(156)	
Advances to related parties		(249)	(2,742)	(401)	(2,745
Repayment on related party loans		260	(_,, · · _)	303	193
Capital contributed by non-controlling interest			_	40	_
Net cash provided by financing activities	S	<u>2,598</u> \$	215,357		236,455
Not each (outflow) inflow	s	(105 502) 0	10/ 0/2	(144.337) (107.7(2)
Net cash (outflow) inflow	3	(• •)• • •) •	186,862 S 292		
Net effects of foreign exchange		(120)		(607)	317
Cash, beginning of period		174,428	74,662	213,549	63,736
Cash and cash equivalents, end of period	5	6 <u>68,715</u> \$	261,816	§ <u>68,715</u> \$	261,816

(expressed in thousands of Canadian Dollars except as otherwise indicated)

1. DESCRIPTION OF BUSINESS

The Green Organic Dutchman Holdings Ltd. ("TGODH" or the "Company") was incorporated on November 16, 2016, under the *Canada Business Corporations Act* ("CBCA"). The Company is a reporting issuer domiciled in Canada whose shares and certain warrants are publicly traded on the Toronto Stock Exchange ("TSX") under the symbol "TGOD" and on the OTCQX under the symbol "TGODF". The Company's registered and head office is located at 6205 Airport Road, Building A – Suite 301, Mississauga, ON, L4V 1E3. These unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2019 and 2018 ("Interim Consolidated Financial Statements") include the financial statements of The Green Organic Dutchman Holdings Ltd. and its subsidiaries from the date the Company gained control of each subsidiary.

The Green Organic Dutchman Limited ("TGOD"), a wholly-owned subsidiary of TGODH, is a premium organic licensed producer of cannabis solutions. The principal activities of TGOD include growing and processing medical cannabis as regulated by the Cannabis Act. TGOD obtained a wholesale licence from Health Canada to sell cannabis ("The Licence"). The Licence was amended on multiple occasions to include the extraction, production and sale of cannabis oil and to allow for direct sales to medical patients. The Company also formed a wholly owned subsidiary, Medican Organic Inc. ("Medican"), under the Statuts de constitution of Québec to invest in and develop a property in Valleyfield, Québec and build a facility ("The Québec Facility"). 9371-8633 Québec Inc. ("QuébecCo"), in which the Company has a 49.99% interest, was incorporated under the *Québec Business Corporations Act* ("QBCA") for the purpose of investing in the Valleyfield land for the Québec Facility and operate similarly to TGOD.

On July 5, 2018, the Company expanded its international footprint by investing in a company in Jamaica, Epican Medicinals Ltd ("Epican") which holds various licences issued by the Cannabis Licensing Authority ("CLA") of Jamaica. On January 23, 2019, the Company entered into a joint venture agreement (the "Denmark JV Agreement") with A/S Knud Jepsen ("KJ"), through its wholly owned subsidiary TGOD Europe B.V ("TGOD Europe"), to engage in the research and development of new cannabis genetics and new intellectual property, and the business of cultivating, harvesting, and producing cannabis products. The Company, through various wholly owned subsidiaries and subsidiaries that it controls, also has an exploratory presence in Mexico, Germany, and Greece. The accounting method for these exploratory entities is full consolidation with recognition of a non-controlling interest.

On October 1, 2018, the Company purchased all of the issued and outstanding shares of HemPoland sp. z.o.o. ("HemPoland"), a manufacturer and marketer of premium CBD oils, located in Poland. On June 20, 2019, the Company launched its global strategic hemp division to serve the global hemp CBD market. On April 18, 2019, the Company invested in and entered into a strategic partnership agreement with Califormulations LLC ("Califormulations"), a Delaware based limited liability company, to engage in the research and development of organic cannabinoid beverages (see note 9).

2. BASIS OF PRESENTATION

These Interim Consolidated Financial Statements have been prepared by management in accordance with International Accounting Standard ("IAS") 34, "Interim Financial Reporting" as issued by the International Accounting Standards Board ("IASB"). The same accounting policies and methods of computation were followed in the preparation of these Interim Consolidated Financial Statements as those disclosed in the Company's annual audited consolidated financial statements for the year ended December 31, 2018, except for the newly issued standards and amendments, and changes to policies as discussed below.

These Interim Consolidated Financial Statements do not include all of the information required for full annual consolidated financial statements and accordingly should be read in conjunction with the annual audited consolidated financial statements for the year ended December 31, 2018 which are made available on SEDAR at www.sedar.com.

These Interim Consolidated Financial Statements were approved by the Board of Directors of the Company and authorized for issue by the Board of Directors of the Company on August 13, 2019.

(expressed in thousands of Canadian Dollars except as otherwise indicated)

3. SIGNIFICANT ACCOUNTING POLICIES

The preparation of these Interim Consolidated Financial Statements requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the Interim Consolidated Financial Statements are consistent with those disclosed in the notes to the annual consolidated financial statements for the year ended December 31, 2018 with the exception of leases, as discussed below.

[a] New standards, interpretations and amendments adopted by the Company

IFRS 16 Leases ("IFRS 16")

Effective January 1, 2019, the Company adopted IFRS 16, which supersedes previous accounting standards for leases, including IAS 17, *Leases* ("IAS 17") and IFRIC 4, *Determining whether an arrangement contains a lease* ("IFRIC 4").

IFRS 16 introduced a single accounting model for lessees unless the underlying asset is of low value or less than twelve months in duration. A lessee is required to recognize, on its statements of financial position, a right-of-use asset, representing its right to use the underlying lease asset, and a lease liability, representing its obligation to make lease payments. As a result of adopting IFRS 16, the Company has recognized an increase to both assets and liabilities on the consolidated statements of financial position, as well as a decrease to general and administrative expenses (for the removal of rent expense for leases), an increase to depreciation and amortization (due to depreciation of the right-of-use assets), and an increase to finance costs (due to accretion of the lease liability). The accounting treatment for lessors remains largely the same as under IAS 17.

The Company adopted IFRS 16 with the cumulative effect of initial application recognized as an adjustment to retained earnings within shareholders' equity on January 1, 2019. The Company has not restated comparative figures for 2018. At transition, we applied the practical expedient available to us as lessee that allows us to maintain our lease assessments made under IAS 17 and IFRIC 4 for existing contracts. Therefore, the definition of a lease under IFRS 16 was applied only to contracts entered into or changed after January 1, 2019.

For leases that were classified as operating leases under IAS 17, lease liabilities at transition have been measured at the present value of remaining lease payments, discounted at the related incremental borrowing rate as at January 1, 2019, or if available, the interest rate implicit in the lease contract. Generally, right-of-use assets at transition have been measured at an amount equal to the corresponding lease liabilities, adjusted for any prepaid or accrued rent relating to that lease. For certain leases where the Company has readily available information, the Company has elected to measure the right-of-use assets at their carrying amounts as if IFRS 16 had been applied since the lease commencement date using the related incremental borrowing rate for the remaining lease period as at January 1, 2019.

On transition, the Company has elected to apply the recognition exemptions on short-term leases and low-value leases; however, the Company may choose to not elect the recognition exemptions on a class-by-class basis for new classes, and lease-by-lease basis, respectively, in the future. The Company does not currently have any contracts where it acts as the lessor.

(expressed in thousands of Canadian Dollars except as otherwise indicated)

Reconciliation of condensed consolidated statement of financial position as at January 1, 2019

Below is the effect of transition to IFRS 16 on the impacted line items of the Company's interim condensed consolidated statement of financial position as at January 1, 2019:

	Reference		As reported as at December 31, 2018	Effect of IFRS 16 transition		Subsequent to transition as at January 1, 2019
ASSETS						
Non-current assets						
Property, plant and equipment	(i)	\$_	107,529	\$ 1,279	\$	108,808
Total assets		\$_	445,957	\$ 1,279	\$	447,236
LIABILITIES AND SHAREHOLDERS' EQUITY						
Current liabilities						
Current portion of lease liabilities	(i)	\$	151	\$ 112	\$	263
Non-current liabilities						
Lease liabilities	(i)		261	\$ 1,207		1,468
Total liabilities		\$	32,262	\$ 1,319	\$	33,581
Shareholders' equity						
Deficit			(58,823)	(40))	(58,863)
Total Shareholders' Equity		\$	413,695	\$ (40)	\$	413,655
Total Liabilities and Shareholders' Equity		\$	445,957	\$ 1,279	\$	447,236

(i) Right-of-use assets and lease liabilities

The Company has recorded a right-of-use asset and a lease liability for all existing leases at the lease commencement date, which is January 1, 2019 for the purposes of adoption. The lease liability has been initially measured at the present value of lease payments that remain to be paid at the commencement date. Lease payments included in the measurement of the lease liability include:

- fixed payments, including in-substance fixed payments;
- variable lease payments that depend on an index or rate;
- amounts expected to be payable under a residual value guarantee; and
- the exercise price under a purchase option that the Company is reasonably certain to exercise, lease payments in an optional renewal period if the Company is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Company is reasonably certain not to terminate early.

After transition, the right-of-use assets will initially be measured at cost, consisting of:

- the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date; plus
- any initial direct costs incurred; and
- an estimate of costs to dismantle and remove the underlying asset or restore the site on which it is located; less
- any lease incentives received.

The right-of-use assets will typically be depreciated on a straight-line basis over the lease term, unless the Company expects to obtain ownership of the leased asset at the end of the lease. The lease term will consist of:

- the non-cancellable period of the lease;
- periods covered by options to extend the lease, where we are reasonably certain to exercise the option; and
- periods covered by options to terminate the lease, where we are reasonably certain not to exercise the option.

The Company's weighted average borrowing rate applied to lease liabilities at January 1, 2019 is 2.99%. The difference between operating lease commitments disclosed as at December 31, 2018 under IAS 17 and discounted using the incremental borrowing rate at the date of initial application on January 1, 2019 and the lease liabilities recognized at the date of initial application is not significant. See note 11 for accounting policies, including estimates and judgments, to be used for accounting for leases under IFRS 16.

(expressed in thousands of Canadian Dollars except as otherwise indicated)

[b] Comparative figures

During the current period, the Company retrospectively reclassified certain immaterial cash flow information presented in the statement of cash flows. The Company has reclassified the change in accounts payable related to additions to property, plant and equipment and intangible assets from the investing section of the statement of cash flows to the operating section of the statement of cash flows. The reclassification does not affect the total change in cash for these periods or the opening and closing balances of cash. The reclassification has the following effect on the statement of cash flows for the respective periods not ed below:

	For the three months ended						
	March 31, 2018 (as previously reported)	Reclassification	March 31, 2018 (as reclassified)				
Operating activities							
Changes in non-cash operating working capital items	\$ 1,253 \$	(901) \$	352				
Net cash used in operating activities	(3,774)	(901)	(4,675)				
Investing activities							
Additions to property, plant and equipment	\$ (4,324) \$	901 \$	(3,423)				
Net cash used in investing activities	(6,495)	901	(5,594)				

		For the t	three months end	For the six months ended			
	June 30 (as prev report	iously	eclassification	June 30, 2018 (as reclassified)	June 30, 2018 (as previously reported)	Reclassification	June 30, 2018 (as reclassified)
Operating activities							
Changes in non-cash operating working capital items	\$	(581)\$	(7,997)\$	(8,578)	672	\$ (8,898) \$	(8,226)
Net cash used in operating activities		(7,196)	(7,997)	(15,193)	(10,898)	(8,898)	(19,796)
Investing activities							
Additions to property, plant and equipment	(21,099)	7,997	(13,102)	(25,423)	8,898	(16,525)
Net cash used in investing activities	(21,299)	7,997	(13,302)	(27,794)	8,898	(18,896)

	For t	he three months e	nde	ed	For the nine months ended			
	September 30, 2018 (as previously reported)	Reclassification		September 30, 2018 (as reclassified)	September 30, 2018 (as previously reported)	Reclassification	September 30, 2018 (as reclassified)	
Operating activities								
Changes in non-cash operating working capital items	\$ (5,222) \$	220	\$	(5,002)	(4,550) \$	(8,678)\$	(13,228)	
Net cash used in operating activities	(13,900)	220		(13,680)	(24,797)	(8,678)	(33,475)	
Investing activities								
Change in non-cash working capital related to property, plant and equipment	\$ 220 \$	6 (220)	\$	—	(8,678) \$	8,678 \$	_	
Net cash used in investing activities	(41,527)	(220))	(41,747)	(69,321)	8,678	(60,643)	

For the year ended						
, (Reclassification	December 31, 2018 (as reclassified)				
\$ (11,057) \$	(17,302) \$	(28,359)				
(44,965)	(17,302)	(62,267)				
\$ (17,302) \$	17,302 \$	—				
(118,178)	17,302	(100,876)				
	December 31, 2018 (as previously reported) \$ (11,057) \$ (44,965) \$ (17,302) \$	December 31, 2018 (as previously reported) Reclassification \$ (11,057) \$ (17,302) \$ (44,965) (17,302) \$ (17,302) \$ (17,302) \$ 17,302 \$				

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

	For	the three months ended	
	March 31, 2019 (as previously reported)	Reclassification	March 31, 2019 (as reclassified)
Operating activities			
Changes in non-cash operating working capital items	\$ 11,823 \$	(22,958) \$	(11,135)
Net cash used in operating activities	451	(22,958)	(22,507)
Investing activities			
Change in non-cash working capital related to property, plant and equipment	\$ (22,666) \$	22,666 \$	_
Change in non-cash working capital related to intangible assets	(292)	292	_
Net cash used in investing activities	(49,860)	22,958	(26,902)

Certain other comparative figures have been reclassified to conform to the current period's presentation.

[c] Change in functional currency of HemPoland

For the three and six months ended June 30, 2019, the functional currency of the Company's wholly owned subsidiary, HemPoland, was determined to be the European Euro, where it was previously the Polish Zloty. The Company determined there were no material impacts to the current period or prior periods' financial statements as a result of this change.

[d] New standards, interpretations and amendments not yet adopted by the Company.

The Company has not identified any relevant material new standards, interpretations and amendments to be adopted by the Company in future periods.

4. BIOLOGICAL ASSETS

As at June 30, 2019, the Company's biological assets consisted of cannabis seeds and cannabis plants. The continuity of biological assets is as follows:

	Сарі	italized cost	logical asset fair value djustment	Amount
Balance, January 1, 2018		—		_
Purchase of seeds		44		44
Unrealized gain on changes in fair value of biological assets		_	304	304
Production costs capitalized		441	_	441
Transfer to inventory upon harvest		(220)	(174)	(394)
Balance, December 31, 2018	\$	265 \$	130 \$	395
Purchase of seeds		12	_	12
Unrealized gain on changes in fair value of biological assets		—	215	215
Production costs capitalized		229	_	229
Transfer to inventory upon harvest		(268)	(222)	(490)
Balance, March 31, 2019	\$	238 \$	123 \$	361
Unrealized gain on changes in fair value of biological assets		_	10	10
Production costs capitalized		292	_	292
Transfer to inventory upon harvest		(285)	(66)	(351)
Balance, June 30, 2019	\$	245 \$	67 \$	312

The Company measures its biological assets at their fair values less estimated costs to sell. This is determined using a model which estimates the expected harvest yields in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price per gram and also for any additional costs to be incurred, such as post-harvest costs.

The following significant unobservable inputs, all of which are classified as level three on the fair value hierarchy, were used by management as part of this model:

The Green Organic Dutchman Holdings Ltd.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

- Estimated selling price per gram calculated as the expected approximate future per gram selling prices of the Company's cannabis products. With no extensive history of sales, the Company evaluated industry data which is expected to closely approximate the Company's expected selling prices.
- Stage of growth represents the weighted average number of weeks out of the 18 to 22 estimated week growing cycle that biological assets have reached as of the measurement date based on historical experience. The Company accretes fair value on a straight-line basis according to the stage of growth and estimated costs to complete cultivation.
- Yield by plant represents the expected number of grams of finished cannabis inventory which are expected to be obtained from each harvested cannabis plant based on historical experience.

The inter-relationship between these aforementioned unobservable inputs and the fair-value of the biological assets is such that the carrying value of the biological assets as at June 30, 2019 and December 31, 2018 would increase (decrease) if any of these inputs were to be higher (lower).

Other unobservable, level three inputs into the biological asset model include estimated post harvest costs, costs to complete and wastage. These additional level three inputs are not considered to be significant.

The following table quantifies each significant unobservable input, and provides the impact of a 10% increase or decrease in each input would have on the fair value of biological assets:

	As at June 30, 2019	As at December 31, 2018	Impact of 10% change as at June 30, 2019	Impact of 10% change as at December 31, 2018
Estimated selling price per gram (1)	\$2.00 to \$7.14	\$3.00 to \$10.75	\$ 50	\$ 54
Estimated stage of growth	4 to 5 weeks	16.68 weeks	\$ 114	\$ 47
Estimated yield of agricultural produce by plant (2)	54 to 78 grams	52 to 80 grams	\$ 36	\$ 54

- (1) The estimated selling prices per gram include an estimate for the selling price of trim collected as part of the harvesting process which may have value in the oil production process in addition to the estimated selling price direct to medical patients and wholesale pricing.
- (2) The estimated yield varies based on the Company's different cannabis strains.

The Company's estimates are, by their nature, subject to change. Changes in the significant assumptions described will be reflected in future changes in the gain or loss on biological assets. There were no changes between fair value hierarchy levels.

5. INVENTORY

The Company's inventory assets include the following as of June 30, 2019 and December 31, 2018:

	Dried Cannabis	Hemp and Hemp Derived Products	As at June 30, 2019
Raw Materials	\$ _	\$ 701	\$ 701
Work-in-progress	1,242	1,499	2,741
Finished Goods	56	211	267
Packaging and Supplies	106	407	513
Total Inventory	\$ 1,404	\$ 2,818	\$ 4,222
	Dried Cannabis	Hemp and Hemp Derived Products	As at December 31, 2018
Raw Materials	\$ _	\$ 1,649	\$ 1,649
Work-in-progress	394	1,089	1,483
Finished Goods	_	768	768
Packaging and Supplies	_	25	25
Total Inventory	\$ 394	\$ 3,531	\$ 3,925

The Green Organic Dutchman Holdings Ltd. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018 (Unaudited) (expressed in thousands of Canadian Dollars except as otherwise indicated)

6. PROPERTY, PLANT AND EQUIPMENT

				Furniture	ure	Growing		Building	Com	Computer			Consti	Construction	Right-of-use		
Cost:	Land	Bui	Buildings	and fixtures	ures	equipment		improvements	equip	equipment	Automobiles	oiles	in pr	in progress	assets		Total
Balance, December 31, 2018	\$ 2,683	S	2,711	S	196	\$ 1,823	3 \$	669	S	503	s	697	S	99,010	I S	Ś	\$ 108,322
Impact of IFRS 16 transition	I		I		I		I	I		I		I		I	1,279	~	1,279
Transfers	I		I		I	(146)	(9	I		I		(258)		I	404	+	I
Additions	I		I		I	618	8	87		92		14		47,851	93	~	48,755
Disposals	I		I		(-)	I	I	I		I		I		I	I		(7)
Effects of movements in foreign exchange	I		(53)		I	(2	(51)	Ι		I		(22)		(10)	I		(136)
Balance, March 31, 2019	\$ 2,683	S	2,658	\$	189	\$ 2,244	4 \$	786	\$	595	S	431	S	146,851	\$ 1,776	\$ \$	158,213
Transfers						289	6	I				(163)		(625)	499	•	I
Additions	I		I		I	523	3	I		114		100		53,783	1		54,520
Disposals	I		I		I		I	I		I		(5)		I	I		(29)
Effects of movements in foreign exchange	I		6		I	L)	(11)	1		I		5		I	I		1
Balance, June 30, 2019	\$ 2,683	S	2,667	S	189	\$ 3,045	5 S	787	S	709	S	341	\$	200,009	\$ 2,275	8	212,705
Accumulated depreciation:																	
Balance, December 31, 2018	د ا	S	96	S	32	\$ 238	8	231	\$	122	S	74	S	I	•	\$	793
Transfers	I		I		I	6)	(96)	I		I		(53)		I	149	~	I
Depreciation	I		22		×	×	84	20		33		æ		I	87	2	262
Effects of movements in foreign exchange	I		I		Ξ	(1	(14)	Ι		(14)		I		I	I	ı	(29)
Balance, March 31, 2019	ۍ ۹	Ś	118	\$	39	S 212	2	251	\$	141	S	29	\$	I	\$ 236	s.	1,026
Depreciation			38		8	7	77	21		41		32			205	0	422
Effects of movements in foreign exchange	I		I		Ι	1	10	I		13		(9)		I			17
Balance, June 30, 2019	۲ ج	÷	156	s	47	\$ 299	8	272	S	195	s	<u>55</u>	÷	ľ	\$ 441	÷	1,465

11

\$ 211,240

1,834

\$

200,009

Ś

286

\$

514

Ś

515

\$

2,746

\$

142

Ś

\$ 2,511

\$ 2,683

Net book value, June 30, 2019

The Green Organic Dutchman Holdings Ltd. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018 (Unaudited) (expressed in thousands of Canadian Dollars except as otherwise indicated)

					Furniture	Growing	ing	Building	Computer			Construction in	tion in		
Cost:	Land		Buildin		and fixtures	equipment	nent	improvements	equipment		Automobiles	progress	'ess		Total
Balance, December 31, 2017	\$ 2,621		\$	620	\$ 6	S	363	\$ 471	\$ 108	S	99	s	2,960	S	7,215
Additions	v	62		I	154		280	40	100		35		3,653		4,324
Balance, March 31, 2018	2,683	83		620	160		643	511	208		101		6,613		11,539
Additions					1		96		105		164		20,734		21,099
Transfers		I		971	I		I	I	1		I		(971)		I
Balance, June 30, 2018	2,683	83	1,	591	160		739	511	313		265		26,376		32,638
Additions from a business combination		I	1,0	062	1		641	11	 		378		23		2,116
Additions	•	I		I	35		403	177	190		101		72,604		73,510
Transfers		Í		I	I		I	I	I		I		I		I
Impairment of fixed assets		I		I	I		(14)	I	I		(20)		I		(84)
Effects of movements in foreign exchange	•	I		58	I		54	I	I		23		7		142
Balance, December 31, 2018	\$ 2,683		\$ 2,	711	\$ 196	\$,823	\$ 669	\$ 503	S	697	.s	99,010	S	108,322
Accumulated denreciation:															
Balance, December 31, 2017	s	1	S	23	\$	S	52	\$ 145	\$ 16	S	12	S	I	\$	250
Depreciation	•	I		5	1		22	20	12		5		I		65
Balance, March 31, 2018				28	3		74	165	28		17				315
Depreciation				6	8		35	21	21		8				102
Balance, June 30, 2018		I		37	11		109	186	49		25		I		417
Depreciation				59	21		115	45	72		48		I		360
Effects of movements in foreign exchange		I		I	I		14	I	1		1		I		16
Balance, December 31, 2018	S		\$	96	\$ 32	S	238	\$ 231	\$ 122	S	74	S	I	\$	793

107,529

∽

99,010

\$

623

 $\boldsymbol{\diamond}$

381

\$

468

\$

1,585

\$

164

 $\boldsymbol{\diamond}$

2,615

Ś

\$ 2,683

Net book value, December 31, 2018

(expressed in thousands of Canadian Dollars except as otherwise indicated)

7. INTANGIBLE ASSETS AND GOODWILL

A continuity of the intangible assets is as follows:

Cost:	C	lealth anada icence		chnology icences	v	Website		stribution hannels	Į	Brands	a	Other cquired rights	G	oodwill		Total
Balance, January 1, 2019	\$	5,870	\$	200	\$	_	\$	5,904	\$	1,054	\$	1,344	\$	10,702	\$	25,074
Additions				1,205		_										1,205
Effect of movements in foreign exchange		_		—		_		(249)		(44)		(56)		(368)		(717)
Balance, March 31, 2019	\$	5,870	\$	1,405	\$	_	\$	5,655	\$	1,010	\$	1,288	\$	10,334	\$	25,562
Additions		—		397		400		—		—		—		—		797
Effect of movements in foreign exchange		—		—		_		(34)		(6)		(7)		(47)		(94)
Balance, June 30, 2019	\$	5,870	\$	1,802	\$	400	\$	5,621	\$	1,004	\$	1,281	\$	10,287	\$	26,265
Accumulated amortization: Balance, January 1, 2019 Amortization for the period Effect of movements in foreign exchange	\$	590 74	\$	22 8	\$	-	\$	105 101 (3)	\$	19 18 (1)	\$	101 98 (3)	\$	-	\$	837 299 (7)
Balance, March 31, 2019	\$	664	\$	30	\$		\$	203	\$	36	\$	196	\$	_	\$	1.129
Amortization for the period	<u>ф</u>	74	φ			_	φ	101	φ	18	φ	114	Φ	_	φ	316
Effect of movements in foreign exchange		_		_		_		(3)				(4)		_		(7)
Balance, June 30, 2019	\$	738	\$	39	\$		\$	301	\$	54	\$	306	\$		\$	1,438
Net book value, June 30, 2019	\$	5,132	\$	1,763	\$	400	\$	5,320	\$	950	\$	975	\$	10,287	\$	24,827
		Health anada	Tee	chnology	Dis	stribution				Other cquired						

	anada icence	nology cences	ribution annels	В	rands	quired ights	G	oodwill	 Total
Cost:									
Balance, January 1, 2018	\$ 5,870	\$ —	\$ —	\$	—	\$ —	\$	2,007	\$ 7,877
Additions		200	—		—	26		—	226
Additions from a business combination	—	_	5,600		1,000	1,250		8,247	16,097
Effect of movements in foreign exchange	_	_	304		54	68		448	874
Balance, December 31, 2018	\$ 5,870	\$ 200	\$ 5,904	\$	1,054	\$ 1,344	\$	10,702	\$ 25,074
Accumulated amortization:									
Balance, January 1, 2018	\$ 295	\$ 	\$ —	\$	—	\$ —	\$	—	\$ 295
Amortization for the period	295	22	101		18	97		—	533
Effect of movements in foreign exchange	—	_	4		1	4			9
Balance, December 31, 2018	\$ 590	\$ 22	\$ 105	\$	19	\$ 101	\$		\$ 837
Net book value, December 31, 2018	\$ 5,280	\$ 178	\$ 5,799	\$	1,035	\$ 1,243	\$	10,702	\$ 24,237

(expressed in thousands of Canadian Dollars except as otherwise indicated)

8. INVESTMENTS IN ASSOCIATES

The carrying value of investments in associates consist of:

			Balance,			
	Note	% ownership	December 31, 2018	Share of net income (loss)	OCI foreign exchange loss	Balance, June 30, 2019
QuebecCo	8 [a]	49.99%	2,171	15	· _	2,186
Epican	8 [b]	49.18%	8,773	(467)	(595)	7,711
			10,944	(452)	(595)	9,897

	Note	% ownership	Balance, December 31, 2017	Additions	Transaction costs	Share of net loss	OCI foreign exchange loss	Balance, December 31, 2018
QuebecCo	8 [a]	49.99%	_	2,001	170	_	_	2,171
Epican	8 [b]	49.18%	_	9,869	90	(1,136)	(50)	8,773
			_	11,870	260	(1,136)	(50)	10,944

The following is a summary of financial information for the Company's associates at June 30, 2019 and for the six months then ended (at 100%):

	Quél	pecCo	Ep	ican
	As at June 30, 2019	As at January 1, 2019	As at June 30, 2019	As at January 1, 2019
Assets	·			
Current assets	37	—	4,180	5,364
Non-current assets	4,002	4,002	17,671	19,071
Total assets	4,039	4,002	21,851	24,435
Liabilities				
Current liabilities	97	90	607	631
Non-current liabilities	—	—	4,371	4,774
Total liabilities	97	90	4,978	5,405
-	For the three months ended June 30, 2019	For the six months ended June 30, 2019	For the three months ended June 30, 2019	For the six months ended June 30, 2019
Revenue	12	37	565	1,041
Expenses			1,043	1,991
Net profit (loss) from operations	12	37	(478)	(950)
Effect of foreign currency translation			(1,109)	(1,207)
Comprehensive income (loss)	10	30	(1,587)	(2,157)

No profit and loss activity was recorded for the three and six months ended June 30, 2018 for QuébecCo or Epican.

[a] Investment in QuébecCo

On January 12, 2018, the Company completed the purchase of 2,001,134 Class A shares of QuébecCo representing a 49.99% interest in the company. The purchase price paid was \$2,001 and \$170 in transaction costs were capitalized in accordance with IAS 28 *Investment in Associates*. QuébecCo holds a property located in the City of Salaberry-de-Valleyfield, Québec.

[b] Investment in Epican

On July 5, 2018, the Company purchased 5,759,788 shares of Epican in exchange for total cash consideration of \$8,348 and 247,353 shares of the Company, the fair value of which was determined to be approximately \$1,521.

(expressed in thousands of Canadian Dollars except as otherwise indicated)

9. OTHER ASSETS

On April 18, 2019, the Company purchased 580,714 Class A units of Califormulations LLC ("Califormulations"), a US based beverage company, representing a 15% ownership in Califormulations, for total cash consideration of \$1,434. In accordance with the Company's accounting policies with respect to IFRS 9 Financial Instruments disclosed in the audited Consolidated Financial Statements, the investment met the criteria for initial recognition at fair value. In conjunction with the purchase, the Company's issued a promissory note to Califormulations in the amount of \$1,451 to be used for working capital purposes. The Company's investment in Califormulations is recorded in other assets.

10. BUSINESS COMBINATION

Acquisition of HemPoland

On October 1, 2018, the Company entered into a share purchase agreement to purchase all of the shares of HemPoland, a manufacturer and seller of premium cannabidiols ("CBD") oils. In connection with the transaction, the Company paid \$9,931 in cash and issued 1,968,323 restricted shares that are escrowed until September 30, 2021. Additionally, there is contingent consideration of up to 3,047,723 shares based on HemPoland achieving certain earnings targets by the end of the 2021 financial year which may be settled in cash pursuant to the terms of the agreement at the Company's option.

The Company is continuing the process of determining the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired may be subject to adjustments pending completion of final valuations and post-closing adjustments as permitted by IFRS. The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed at the acquisition date:

	Note	Number of shares	Sha	are price	A	mount
Consideration paid						
Cash						9,931
Restricted shares issued	(i)	1,968,323	\$	6.75		7,972
Contingent consideration	(ii)					688
Total consideration paid					\$	18,591
Net assets acquired						
Current assets						
Cash and cash equivalents						1,520
Accounts receivable						420
Refundable Sales Taxes Receivable						462
Prepaids						17
Inventory						2,600
Non-current assets						
Property, plant and equipment						2,116
Distributor relationships						5,600
CannibiGold brand						1,000
Non-compete agreements						1,250
Goodwill						8,247
Total assets						23,232
Current liabilities						
Accounts payable and accrued liabilities						1,254
Income taxes payable						675
Short-term loans						653
Current portion of lease liabilities						86
Non-current liabilities						
Lease liabilites						203
Deferred tax liability						1,770
Total liabilities						4,641
Total net assets acquired					\$	18,591

(expressed in thousands of Canadian Dollars except as otherwise indicated)

- (i) Recorded at fair value, which was determined using a share price and exercise price of \$6.75, term of three years, discount rate of 2.31% and volatility of 75% with a corresponding entry included in contributed surplus.
- (ii) Subject to revaluation at each period end. As at June 30, 2019, the contingent consideration was revalued to \$488, resulting in a gain on revaluation of \$175 and \$200 for the three and six months ended June 30, 2019, respectively.

The Company recognized \$852 in transaction costs in the strategic business initiatives line item in the consolidated statement of loss and other comprehensive loss in connection with the business combination for the year-ended December 31, 2018. The net loss for the period from October 1, 2018 to December 31, 2018 for HemPoland was \$1,590. Proforma results of operations of HemPoland for the year-ended ended December 31, 2018 have not been presented as it would be impracticable to do so given changes to some of HemPoland's operations.

11. LEASES

Accounting policy

At inception of a contract, the Company assesses whether that contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether:

- the contract involves the use of an identified asset;
- the Company has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and
- the Company has the right to direct the use of the asset.

Lessee accounting

The Company records a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, consisting of:

- the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date; plus
- any initial direct costs incurred; and
- an estimate of cost to dismantle and remove the underlying asset or restore the site on which it is located; less
- any lease incentives received.

The right-of-use asset is typically depreciated on a straight-line basis over the lease term, unless the Company expects to obtain ownership of the leased asset at the end of the lease. The lease term consists of:

- the non-cancellable period of the lease;
- periods covered by options to extend the lease, where we are reasonably certain the exercise the option; and
- periods covered by options to terminate the lease, where we are reasonably certain not to exercise the option.

If the Company expects to obtain ownership of the leased asset at the end of the lease, the Company depreciates the right-of-use asset over the underlying asset's estimated useful life. In addition, right-of-use assets are periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of lease liabilities.

Lease liabilities are initially measured at the present value of lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. The Company uses the relevant incremental borrowing rate as the interest rate implicit in the leases cannot be readily determined. Lease liabilities are subsequently measured at amortized cost using the effective interest rate method.

Lease payments included in the measurement of lease liabilities:

- fixed payments, including in-substance fixed payments;
- variable lease payments that depend on an index or rate;
- amounts expected to be payable under a residual value guarantee; and
- the exercise price under a purchase option that we are reasonably certain to exercise, lease payments in an optional renewal period if we are reasonably certain to exercise an extension option, and penalties for early termination of a lease unless we are reasonably certain not to terminate early.

Lease liabilities are remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company y

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

changes its assessment of whether or not it will exercise a purchase, extension, or termination option. When lease liabilities are remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use assets.

Lease liabilities are also remeasured when the underlying lease contract is amended. When there is a decrease in contract scope, the lease liability and right-of-use asset will decrease relative to this change with the difference recorded in net income prior to the remeasurement of the lease liability.

Certain leases require the Company to make payments that relate to property taxes, insurance, and other non-rental cost. These non-rental costs are typically variable and are not included in the calculation of the right-of-use asset or lease liability.

Use of estimates and judgments

Estimates

The Company estimates the lease term by considering the facts and circumstances that can create an economic incentive to exercise an extension option, or not exercise a termination option. The Company makes certain qualitative and quantitative assumptions when deriving the value of the economic incentive.

Judgments

The Company makes judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset and should provide the Company with the right to substantially all of the economic benefits from the use of the asset.

The Company also makes judgments in determining whether or not it has the right to control the use of the identified asset. The Company has that right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decisions about how and for what purpose the asset is used are predetermined, the Company has the right to direct the use of the asset if it has the right to operate the asset or if it designed the asset in a way that predetermines how and for what purpose the asset will be used.

The Company makes judgments in determining the incremental borrowing rate used to measure its lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that the Company would have to pay to borrow at a similar term and with a similar security.

Certain of the Company's leases contain extension or renewal options that are exercisable only by the Company and not by the lessor. At lease commencement, the Company assesses whether it is reasonably certain to exercise any of the extension options based on the expected economic return from the lease. The Company periodically reassesses whether it is reasonably certain to exercise the options and account for any changes at the date of the reassessment.

Explanatory information

Lease liabilities

Below is a summary of the activity related to the Company's lease liabilities for the six months ended June 30, 2019:

	s at 60, 2019
Lease liabilities, December 31, 2018	\$ 412
Effect of adoption of IFRS 16, January 1, 2019	1,319
Net additions	319
Interest on lease liabilities	61
Interest payments on lease liabilities	(61)
Principal payments on lease liabilities	(164)
Foreign exchange differences	(14)
Lease liabilities, June 30, 2019	\$ 1,872
Current portion lease liabilities, June 30, 2019	416
Long-term portion lease liabilities, June 30, 2019	1,456

(expressed in thousands of Canadian Dollars except as otherwise indicated)

12. CONTRIBUTED SURPLUS

The Company's contributed surplus balances include the following:

	Notes	Reserve for share based payments \$	Reserve for warrants \$	Reserve for special warrants and underwriter special warrants	Contributed surplus	Escrowed share units \$	Total \$
Balance, January 1, 2019		8,053	62,801	610	501	7,972	79,937
Stock based compensation	12[a]	3,381		—	—	_	3,381
Exercise of stock options	12[a]	(73)		_	_	_	(73)
Exercise of warrants	12[b]		(1,749)	_	_	_	(1,749)
Balance, March 31, 2019		11,361	61,052	610	501	7,972	81,496
Stock based compensation	12[a]	4,407	_	—	· –	—	4,407
Exercise of stock options	12[a]	(135)	_	—	_	_	(135)
Exercise of warrants	12[b]	_	(390)	—	_	_	(390)
Cancellation of warrants	12[b]		(10)		10	_	
Issuance of convertible units	12[e]	300					300
Balance, June 30, 2019		15,933	60,652	610	511	7,972	85,678

	Reserve for share based payments	Reserve for warrants	Reserve for special warrants and underwriter special warrants	Contributed surplus	Total
Balance, January 1, 2018	4,413	13,883	_	—	18,296
Private placement of units		4,359	—		4,359
Finders compensation - Units	_	208	_	_	208
Issuance of units held in trust		12	_		12
Stock based compensation	(1,284)	_	_		(1,284)
Exercise of stock options	(7)	_	_		(7)
Balance, March 31, 2018	3,122	18,462	· —	_	21,584
Initial public offering	_	8,508			8,508
Initial public offering - over-allotment		1,277	_		1,277
Conversion of subscription receipts	_	26,773	_	_	26,773
Exercise of stock options	(291)	_	_		(291)
Exercise of warrants		(1,381)	—	1,041	(340)
Issuance of special warrants	_	_	25,024	_	25,024
Issuance of underwriter special warrants		_	610		610
Stock based compensation	1,716	6	_	_	1,722
Share issue costs		(710)	(2,285)	_	(2,995)
Balance, June 30, 2018	4,547	52,935	23,349	1,041	81,872

[a] Share based payments

The Company initiated an Employee Stock Option Plan (the "Original Plan") on February 2, 2017 that is administered by the Board of Directors of the Company which establishes exercise prices, at not less than the market price at the date of grant, and expiry dates, which have been set at three years from issuance. Options under the Original Plan remain exercisable in increments with one third being exercisable on each of the first, second and third anniversaries from the date of the grant, except as otherwise approved by the Board of Directors.

On January 31, 2018, the Company adopted a new stock options plan which superseded the Original Plan. There were 4,804,132 options issued and outstanding pursuant to the Original Plan, which will remain exercisable until their expiry or cancellation and in accordance with their vesting schedules. Under the Company's Amended Option Plan, adopted at the Annual General and Special Meeting ("AG&SM") on December 6, 2018, options may be granted for up to 10% of the common shares outstanding at

The Green Organic Dutchman Holdings Ltd.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

the time of the grant for a term not exceeding five years. The exercise price of the options under the Amended Option Plan is fixed by the Board of Directors of the Company at the time of the grant at the market price of the common shares, subject to all applicable regulatory requirements. As at June 30, 2019, total options outstanding were 16,955,800. For the three and six months ended June 30, 2019, the Company recorded \$4,378 and \$7,736, respectively in non-cash share-based compensation expense pursuant to the grant of stock options (June 30, 2018 -\$1,752 and \$2,782, respectively) and \$29 and \$52, respectively in non-cash restricted share unit compensation (three and six months ended June 30, 2018 - \$nil and \$nil, respectively). The Company recognized no stock-based compensation expense for the three and six months ended June 30, 2019 in the form of finders' units (three and six months ended June 30, 2018 - \$nil and \$1,142).

The following is a summary of the changes in the Company's ESOP options:

	June 30,	2019	December 31, 2018			
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price		
Outstanding - beginning of period	12,430,732	2.83	9,436,000	0.82		
Granted	5,035,000	4.31	8,026,000	4.04		
Exercised	(369,933)	0.86	(3,929,868)	0.62		
Cancelled/Expired	(139,999)	2.90	(1,101,400)	1.78		
Outstanding, end of period	16,955,800	3.31	12,430,732	2.83		
Exercisable, end of period	4,703,333	2.26	1,670,532	0.82		

The Green Organic Dutchman Holdings Ltd.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

	Options	Options	Exercise	Weighted Average remaining contractual life of	
~	Outstanding	Exercisable	Price	outstanding	
Grant date	#	#	\$	options in years	Expiry Date
February 7, 2017	1,853,732	1,243,332	0.50	0.61	February 7, 2020
June 1, 2017	916,000	439,000	1.15	0.92	June 1, 2020
October 2, 2017	1,614,000	705,600	1.15	1.26	October 2, 2020
January 8, 2018	400,000	128,000	1.65	1.53	January 8, 2021
January 12, 2018	20,400	2,400	1.65	1.54	January 12, 2021
March 28, 2018	4,705,001	1,908,334	3.65	1.75	March 28, 2021
May 28, 2018	250,000	83,333	4.12	3.91	May 28, 2023
June 25, 2018	80,000	26,667	6.91	3.99	June 25, 2023
June 26, 2018	200,000	66,667	6.83	3.99	June 26, 2023
August 2, 2018	210,000	_	5.50	4.09	August 2, 2023
August 13, 2018	550,000	_	5.25	4.12	August 13, 2023
September 7, 2018	25,000	_	6.20	4.19	September 7, 2023
October 1, 2018	250,000	—	6.75	4.18	September 1, 2023
October 9, 2018	160,000	_	6.37	4.28	October 9, 2023
October 22, 2018	75,000	—	4.93	4.32	October 22, 2023
October 25, 2018	450,000	—	4.53	4.32	October 25, 2023
November 9, 2018	75,000	_	3.82	4.36	November 9, 2023
December 4, 2018	25,000	_	3.22	4.43	December 4, 2023
December 14, 2018	75,000	—	3.08	4.46	December 14, 2023
January 8, 2019	600,000	_	2.67	4.53	January 8, 2024
January 14, 2019	600,000	_	2.76	4.55	January 14, 2024
January 21, 2019	75,000	_	2.99	4.56	January 21, 2024
January 28, 2019	200,000	_	3.41	4.58	January 28, 2024
February 1, 2019	75,000	_	3.77	4.59	February 1, 2024
March 4, 2019	75,000	_	4.09	4.68	March 4, 2024
March 11, 2019	210,000	_	4.30	4.70	March 11, 2024
March 12, 2019	50,000	_	4.37	4.70	March 12, 2024
March 18, 2019	50,000	_	4.42	4.72	March 18, 2024
March 19, 2019	50,000	_	4.74	4.72	March 19, 2024
March 22, 2019	2,736,667	100,000	5.13	4.73	March 22, 2024
April 8, 2019	50,000		4.47	4.78	April 8, 2024
April 15, 2019	50,000		4.24	4.80	April 15, 2024
May 13, 2019	150,000		4.11	4.87	May 13, 2024
May 21, 2019	50,000		3.86	4.90	May 21, 2024
Balance, June 30, 2019	16,955,800	4,703,333		2.74	

In determining the amount of share-based compensation, the Company uses the Black-Scholes option pricing model to establish the fair value as at the grant date of options granted. The following assumptions were used to measure the values of the stock options granted during the three and six months ended June 30, 2019:

	uary 8, 2019		anuary 4, 2019	anuary 1, 2019	iuary 2019	ebruary , 2019	rch 4, 019	Μ	larch 11, 2019		arch 12, 2019
Risk-free interest rate	1.89%	,	1.89%	1.95%	1.88%	1.86%	1.76%		1.64%	·	1.63%
Expected life of options (years)	3.5		3.5	3.5	3.5	3.5	3.5		3.5		3.5
Expected annualized volatility	85.49%		85.40%	85.18%	85.26%	85.20%	84.42%		84.17%		84.13%
Expected dividend yield	Nil		Nil	Nil	Nil	Nil	Nil		Nil		Nil
Black-Scholes value of each option	\$ 1.39	\$	1.85	\$ 1.69	\$ 2.52	\$ 2.11	\$ 2.44	\$	2.58	\$	2.48

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

	March 18, 2019	March 19, 2019	March 22, 2019	April 8, 2019	April 15, 2019	May 13, 2019	May 21, 2019
Risk-free interest rate	1.60%	1.62%	1.48%	1.60%	1.61%	1.54%	1.65%
Expected life of options (years)	3.5	3.5	3.5	3.5	3.5	3.5	3.5
Expected annualized volatility	84.03%	84.01%	83.87%	83.89%	83.78%	83.11%	82.83%
Expected dividend yield	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Black-Scholes value of each option	\$ 3.12	\$ 3.34	\$ 2.68	\$ 2.45	\$ 2.26	\$ 2.16	\$ 2.40

Volatility was estimated by using the historical volatility of the Company and other companies that the Company considers comparable that have trading and volatility history. The expected life of the options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the expected life of the options is indicative of future trends, which may also not necessarily be the actual outcome.

The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free rate was based upon the Canada government bonds with a remaining term equal to the expected life of the options.

[b] Reserve for warrants

The following table reflects the continuity of warrants:

For the three and six months ended June 30, 2019	Number of warrants	Weighted Average Exercise Price	Amount, net of warrant issue costs
	#	\$	\$
Balance, January 1, 2019	69,759,127	5.07	62,801
Warrants exercised in the period	(4,264,354)	2.15	(1,749)
Balance, March 31, 2019	65,494,773	5.26	61,052
Warrants exercised in the period	(841,057)	2.40	(390)
Warrants cancelled in the period	(25,119)	2.15	(10)
Balance, June 30, 2019	64,628,597	5.29	60,652
For the three and six months ended June 30, 2018	Number of warrants	Weighted Average Exercise Price	Amount, net of warrant issue costs
	#	\$	\$
Balance, January 1, 2018	37,609,842	2.40	13,883

Balance, January 1, 2018	37,609,842	2.40	13,883
Units held in trust	133,750	3.00	72
Issuance of finders' units	692,290	3.00	208
Private placement units	6,462,763	3.00	4,359
Balance, March 31, 2018	44,898,645	2.50	18,522
Initial public offering units	18,118,250	7.00	9,075
Issuance on conversion of subscription receipts	16,666,667	3.00	26,773
Warrants exercised in the period	(4,746,677)	2.63	(1,435)
Balance, June 30, 2018	74,936,885	3.64	52,935

As at June 30, 2019, the following warrants were outstanding:

Expiry Date	tercise Price	Number of Warrants
	\$	#
August 18, 2019	2.15	375,341
May 2, 2020	7.00	15,092,363
October 2, 2020	3.00	130,250
February 28, 2021	3.00	34,483,143
April 19, 2021	9.00	12,592,500
June 26, 2021	9.50	1,955,000
	\$ 5.29	64,628,597

(expressed in thousands of Canadian Dollars except as otherwise indicated)

[c] Restricted share units

Under the Company's Restricted Share Unit Plan, adopted at the AG&SM on December 6, 2018, restricted share units may be granted up to a fixed maximum of 5,000,000 common shares, which entitle the holder to receive one common share without payment of additional consideration at the end of the restricted period, as determined by the Board of Directors of the Company at the time of the grant. For the three and six months ended June 30, 2019, the Company recorded \$29 and \$52, respectively in non-cash stock-based compensation related to restricted share unit compensation (three and six months ended June 30, 2018 - \$nil and \$nil, respectively).

[d] Escrowed share units

In conjunction with the HemPoland acquisition, the Company issued 1,968,323 share units in escrow with a value of \$7,972. (See note 10)

[e] Convertible share units

The Company issued 74,074 convertible share units with a value of \$300 on May 31, 2019 upon the licence from the Danish Medicinal Authority being assigned to *TGOD Genetics A/S*, pursuant to the joint venture agreement with Knud Jepsen. The units convert to common shares over a three-year period beginning on April 19, 2020. For the three months ended June 30, 2019, the Company recorded \$300 in strategic business initiatives to convertible share unit compensation.

13. INCOME TAXES

The Company's combined statutory tax rate is 26.5% for the three and six months ended June 30, 2019 and June 30, 2018, expected to apply for the full year, applied to the pre-tax income of a given three-month period. Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset.

The changes in the net deferred tax liability are provided below:

	For the three 1	nonths ended	For the six months ended			
	June 30, 2019	June 30, 2018	June 30, 2019	June 30, 2018		
	\$	\$	\$	\$		
Balance, beginning of period	1,361	_	1,435	_		
Recognized in income	(157)	_	(171)	—		
Effect of foreign currency translation recognized in other						
comprehensive income	5	_	(55)	_		
Balance, end of period	1,209		1,209			

14. SUPPLEMENTARY CASH FLOW INFORMATION

The changes in non-cash working capital items are as follows:

	For the three m	onths ended	For the six mo	nths ended	
	June 30, 2019	June 30, 2018	June 30, 2019	June 30, 2018	
Prepaid expenses	\$ (2,282) \$	(690) \$	(2,680) \$	(696)	
Harmonized sales tax receivable	(3,555)	(3,032)	(481)	(3,564)	
Accounts receivable	(433)	_	(1,571)	_	
Capitalized cost of biological assets	(7)	(27)	20	(27)	
Inventory	(264)	_	(9)	_	
Other current assets	(1,951)	(720)	(1,972)	(869)	
Other assets	(4,585)	(5,027)	(20,367)	(4,092)	
Accounts payable and accrued liabilities	(301)	918	2,547	1,022	
Total	\$ (13,378) \$	(8,578) \$	(24,513) \$	(8,226)	

(expressed in thousands of Canadian Dollars except as otherwise indicated)

15. COMMITMENTS AND CONTINGENCIES

[a] Construction agreements

The Company has entered into contracts to facilitate the construction of its facilities in Hamilton, Ontario and Salaberry-de-Valleyfield, Québec with various vendors. Pursuant to some of these agreements, the Company has issued letters of credit in the amount of \$5,003 which may be drawn upon in the event of material breaches of the respective agreements. These letters of credit bear conventional rates of interest partially offset by the interest earned on guaranteed investment certificates ("GIC") securing the letters as collateral. The Company has pledged \$5,000 of GICs as collateral, which has been recorded in other assets, due to the long-term nature of the related project. As at June 30, 2019, there have been no breaches and no amounts have been drawn on the letters of credit. As at June 30, 2019, the Company has outstanding deposits on construction related activities of \$29,191 (December 31, 2018 – \$9,431) included in other assets. The Company has also entered into an escrow agreement with its construction partner in Québec whereby \$50,000 has been allocated to the Québec project and these funds are included in restricted cash. During the three months ended June 30, 2019, the Company entered into a similar arrangement with its construction partner in Hamilton for \$4,000 which was also included in restricted cash.

[b] Contractual lease commitments

The Company has entered into contracts at multiple locations, whereby they are committed to make future payments. Management has reviewed these contracts and determined that they do not contain leases as defined under IFRS 16. The total future minimum annual contractually committed payments, other than those already captured under IFRS 16, are \$46. The lease for the office space of the Company's headquarters required the issuance of a letter of credit in the amount \$350, which may be drawn upon by the landlord in the event of a material breach of the agreement. As at June 30, 2019, there have been no breaches and no amounts have been drawn upon this letter of credit.

[c] Revolver facility

On September 1, 2017, the Company executed a revolving credit agreement with a Canadian credit union entitling the Company to borrow to a maximum limit of \$5,000, subject to certain reporting requirements. The credit facility is secured by a GIC and bears a conventional rate of interest. As at June 30, 2019, the Company has not drawn under the revolver loan and is in compliance with the reporting requirements.

[d] Claims and Litigation

From time to time, the Company and/or its subsidiaries may become defendants in legal actions and the Company intends to defend itself rigorously against all legal claims. The Company is subject to certain employment related claims by former employees for which provisions have been recognized only to the extent that they are likely to result in future economic outflows. The Company has also been subject to a claim by former warrant holders for approximately \$1,250. No provisions have been recognized as the Company's position is that the claim is meritless, and the outcome depends on court proceedings. Other than the claims previously described, the Company is not aware of any other material or significant claims against the Company.

[e] Short-term loans

On October 1, 2018, as part of the HemPoland transaction, the Company assumed HemPoland's operating line of credit of which the entire outstanding amount drawn upon of \$146 (400 PLN [in thousands]) was repaid as at March 31, 2019 (December 31, 2018 - \$146). Also, as part of the HemPoland transaction, the Company assumed HemPoland's short-term loan payable on certain premises in Poland, of which \$532 remained outstanding as at June 30, 2019 (December 31, 2018 - \$542).

16. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

[a] Fair values

The Company's financial instruments were comprised of the following as at June 30, 2019: cash and cash equivalents; restricted cash; refundable sales tax receivable; trade receivables; due from related parties; loan receivable; other investments; other current assets; accounts payable and accrued liabilities; short-term loans; contingent consideration and lease liabilities.

The fair values of the financial assets and financial liabilities are determined at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The assumption for the instruments recorded at amortized costs that the instruments fair values approximate their carrying amounts is largely due to the short-term maturities of these instruments. The fair value of the loan receivable related to QuébecCo recorded at fair value through profit and loss is Level 3 and is based on the established underlying fair values of the assets during the recent transaction involving the investment in QuébecCo, whereby it was reasonably concluded to continue to approximate the same fair value as at June 30,

(Unaualiea)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

2019 as compared to the initial recognition date. The fair value of the loan receivable related to Califormulations recorded at fair value through profit and loss was also determined to be Level 3 and given the proximity to its initial recognition is still considered to approximate its fair value.

[b] Fair value hierarchy

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.

During the three and six months ended June 30, 2019, there were no transfers of amounts between levels (three and six months ended June 30, 2018 – none).

[c] Management of risks arising from financial instruments

[i] Market risk

All foreign currencies shown in this note are also presented in thousands.

Foreign currency risk

Foreign currency risk arises due to fluctuations in the fair value or cash flows of financial instruments due to changes in foreign exchange rates. As at December 31, 2018, the Company had no financial assets and liabilities for which cash flows were denominated in foreign currencies other than cash, trade receivables, accounts payable and accrued liabilities, lease liabilities, short-term loans, and due from related parties. The Company does have some suppliers that prefer to contract in foreign currencies. The Company holds cash in U.S. dollars ("US\$"), Euros ("EUR"), and Polish zloty ("PLN"). As at June 30, 2019, the Company had \$11,914 (US\$ 9,022) of cash (December 31, 2018 - \$14,304) and no amounts due from related parties (December 31, 2018 - \$9) denominated in U.S. dollars. As at June 30, 2019, the Company also had \$326 (PLN 930) of cash (December 31, 2018 - \$338) denominated in Polish Zloty and \$770 (EUR 516) of cash (December 31, 2018 - \$450) denominated in Euros ("EUR"). The Company has not used foreign exchange contracts to hedge its exposure to foreign currency cash flows for the three and six months ended June 30, 2019.

Interest rate risk

The Company's exposure to interest rate risk only relates to any investments of surplus cash. The Company may invest surplus cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. As at June 30, 2019, the Company had four term deposits of \$5,191, \$5,000, \$150 and \$92 bearing interest at 2.00%, 2.10%, 1.50%, and 3.05% respectively (December 31, 2018 - \$25,000, \$5,148, \$5,000, \$5,000 and \$150 bearing interest at 1.50%, 1.95%, 2.00%, 2.00% and 1.50%, respectively). The Company also has \$54,000 in restricted cash held in trust related to the Valleyfield and Hamilton construction projects and earning a conventional rate of interest from a reputable top tier Canadian bank.

[ii] Credit risk

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit-related losses in the event of non-performance by the counterparties.

The carrying amount of cash and cash equivalents, trade receivable, refundable sales tax receivable, due from related parties, prepaids and deposits, other assets and loan receivable represents the maximum exposure to credit risk as at June 30, 2019. Since the inception of the Company, no losses have been suffered in relation to any of the above-mentioned assets.

The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors. Credit risk is mitigated by

(expressed in thousands of Canadian Dollars except as otherwise indicated)

entering into sales contracts with only stable, creditworthy parties and through frequent reviews of exposures to individual entities.

The Company assesses the credit risk of trade receivables by evaluating the aging of trade receivables based on the invoice date. The carrying amount of trade receivables is reduced through the use of an allowance account and the amount of the loss is recognized in the consolidated statements of loss and comprehensive loss. When a trade receivable balance is considered uncollectible, it is written off against the allowance for expected credit losses. Subsequent recoveries of amounts previous ly written off are credited against operating expenses in the consolidated statements of loss and comprehensive loss. As at June 30, 2019, the Company's trade receivables are 100% concentrated in Europe. The Company had one customer whose balance comprised 43% of total trade receivables as at June 30, 2019 (December 31, 2018 – two customers at 54% and 14%).

The following tables set forth details of trade receivables, including aging of trade receivables that are not overdue, as well as an analysis of overdue amounts and related allowance for doubtful accounts:

	June 30, 2019 \$	December 31, 2018 \$
Total trade receivables	2,770	1,199
Less allowance for expected credit losses	—	—
Total trade receivables, net	2,770	1,199
Of which		
Current	2,257	1,123
31-90 days	325	59
Over 90 days	188	17
Less allowance for expected credit losses		
Total trade receivables, net	2,770	1,199

[iii] Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements in relation to its current cash balances, maturity schedules and internal budgets.

The Company's contractual maturities due to be paid within one year are represented by its accounts payable and accrued liabilities balances, its short-term loans, and its current portion of finance lease obligations as at June 30, 2019. The Company also has finance lease obligations due beyond one year from the reporting date. The Company has sufficient cash and cash equivalents to meet these obligations.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

17. SEGMENTED INFORMATION

The Company's business activities are conducted through one operating segment which consists of the production and distribution of cannabis and related products. Segment performance is based by region.

[i] Revenue, gross profit and select expenses by region is as follows

The Company's revenues were derived primarily from the Company's operations in Europe from the Company's wholly owned subsidiary, HemPoland. For the three months ended June 30, 2019, the Company had one customer that accounted for 15% of total revenue (three months ended June 30, 2018 - none). For the six months ended June 30, 2019, the Company had two customers that accounted 12% and 10% of total revenue (six months ended June 30, 2018 - none).

	For the three months ended June 30, 2019					For the six months ended June 30, 2019					I	
	E	urope		Canada		Total]	Europe		Canada		Total
Revenue	\$	2,878	\$	18	\$	2,896	\$	5,281	\$	20	\$	5,301
Gross profit (loss)	\$	1,975	\$	(18)	\$	1,957	\$	3,126	\$	198	\$	3,324
Operating expenses, excluding stock based compensation, depreciation and amortization	\$	1,758	\$	11,445	\$	13,203	\$	3,072	\$	22,242	\$	25,314
Share based compensation	\$	—	\$	4,433	\$	4,433	\$	—	\$	7,852	\$	7,852
Depreciation and amortization	\$	434	\$	304	\$	738	\$	715	\$	584	\$	1,299
	·											
Non-operating income	\$	(611)	\$	361	\$	(250)	\$	(562)	\$	1,052	\$	490
					_				_		_	
Net loss	\$	(764)	\$	(15,839)	<u>\$</u>	(16,603)	<u>\$</u>	(1,266)	\$	(29,428)	<u></u>	(30,694)

	For the three months ended (Canada)]	For the six months ended (Canada)
	Ju	ne 30, 2018		June 30, 2018
Revenue	\$	—	\$	
Gross profit	\$	—	\$	
Operating expenses, excluding stock based compensation, depreciation and amortization	\$	7,140	\$	12,288
Share based compensation	\$	1,751	\$	3,925
Depreciation and amortization	\$	181	\$	320
Non-operating income	\$	524	\$	719
Net loss	\$	(8,548)	\$	(15,814)

[ii] Property, plant and equipment, net is domiciled as follows

	June 30, 2019	January 1, 2019	December 31, 2018
Canada \$	207,792	\$ 106,276	\$ 104,997
Europe	3,448	2,532	2,532
\$_	211,240	\$ 108,808	\$107,529

(expressed in thousands of Canadian Dollars except as otherwise indicated)

[iii] Intangible assets and goodwill, net are domiciled as follows

	June 30, 2019		December 31, 2018	
Canada	\$ 9,132	\$	7,287	
Europe	15,525		16,772	
Outside Canada and Europe	170		178	
	\$ 24,827	\$	24,237	

18. CAPITAL MANAGEMENT

The Company's objective is to maintain sufficient capital base to maintain investor, creditor and supplier confidence and to sustain future development of the business and provide the ability to continue as a going concern. Management defines capital as the Company's shareholders' equity. The Board of Directors of the Company does not establish quantitative return on capital criteria for management but rather promotes year over year sustainable profitable growth. The Company currently has not paid any dividends to its shareholders. As at June 30, 2019, total managed capital was comprised of share capital of \$406,004 (December 31, 2018 - \$392,068), contributed surplus of \$85,678 (December 31, 2018 - \$79,937), and accumulated other comprehensive loss of \$1,540 (December 31, 2018 - income of \$513). There were no changes in the Company's approach to capital management during the three and six months ended June 30, 2019 (three and six months ended June 30, 2018 - no changes).

19. EVENTS AFTER THE REPORTING PERIOD

On August 9, 2019, the Company cancelled its unused line of credit with a credit union.